Evidence map›Paper›PMID 42903888›Full record

ArticlehLife2026

Longitudinal analysis identifies bystander-activated innate cytotoxic CD8

Yinchun Chen, Ruiqing Zhou, Limei Zhong, Haimei Deng, Jun Yu, Huijuan Wang, Xiaotao Jiang, Wenjian Mo, Shunqing Wang, Yufeng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in hLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yinchun ChenDepartment of Hematology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Ruiqing ZhouDepartment of Hematology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Limei ZhongDepartment of Laboratory Medicine, Guangdong Second Provincial General Hospital, Guangdong, China.
Haimei DengDepartment of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Guangdong, China.
Jun YuCenter for Medical Research on Innovation and Translation, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Huijuan WangCenter for Medical Research on Innovation and Translation, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Xiaotao JiangDepartment of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, China.
Wenjian MoDepartment of Hematology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Shunqing WangDepartment of Hematology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.
Yufeng LiuDepartment of Hematology, Guangzhou First People's Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction and monitoring of acute graft-versus-host disease (aGVHD) remain challenging in allogeneic hematopoietic stem cell transplantation (allo-HSCT) as current diagnostic approaches rely on symptomatic presentation. Therefore, this study sought to identify predictive biomarkers and therapeutic targets for aGVHD through longitudinal immune monitoring and mechanistic investigations. In this study, peripheral blood samples were collected weekly for 100 days from a group of 115 allo-HSCT recipients. CD38

Indexed as

acute graft-versus-host diseasebiomarkersbystander-activationCD38+HLA-DR+CD8+ T cellsIL-15PI3K/mTOR pathway

Identifiers

PMID42903888
PMCPMC13681502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.